Malde Sachin, Dowson Christopher, Fraser Olivia, Watkins Jane, Khan Muhammed S, Dasgupta Prokar, Sahai Arun
Department of Urology, Guy's and St Thomas' NHS Foundation Trust, King's Health Partners, London, UK.
BJU Int. 2015 Sep;116(3):443-9. doi: 10.1111/bju.13025. Epub 2015 Apr 16.
To evaluate the patient experience of our dedicated botulinum toxin A (BTX-A) service using a validated patient-reported experience measure (PREM) and assess patient-reported satisfaction with treatment.
The first 100 patients who underwent BTX-A treatment for refractory idiopathic detrusor overactivity (IDO) in our institution were contacted for telephone interview. They had all been assessed, injected and followed up in a dedicated BTX-A clinic. Patients were asked to complete a validated PREM - the Client Satisfaction Questionnaire (CSQ-8) - as well as a questionnaire developed in our department to assess satisfaction with the results of the treatment. Most patients received 200 U OnabotulinumtoxinA (Botox(®) ) via an outpatient local anaesthetic flexible cystoscopy technique.
Complete data was available for 72 patients. In all, 49 patients were continuing to receive BTX-A treatment while 23 had opted for no further injections. The overall mean (sd) CSQ-8 satisfaction score was 38.3 (3.3), indicating a high level of patient satisfaction with the service offered in our institution. There was a significant difference in total satisfaction scores between those still receiving BTX-A (mean score 29.8) and those who have discontinued treatment (mean score 25.1) (P < 0.01). Overall patient satisfaction with the result of the treatment was high with an overall mean (sd) score of 8.6 (2.0) on a visual analogue scale. Of those who had discontinued BTX-A, most were either using conservative measures only (44%) or had recommenced anticholinergic medications.
Overall patient satisfaction with the dedicated BTX-A service offered in our institution is high and can result in a positive patient experience. The use of PREMs are advocated in order to fully capture the patient's views of the quality of services and treatments they receive.
使用经过验证的患者报告体验测量工具（PREM）评估我们专门的A型肉毒毒素（BTX-A）服务的患者体验，并评估患者报告的治疗满意度。
联系了在我们机构接受BTX-A治疗难治性特发性逼尿肌过度活动症（IDO）的前100名患者进行电话访谈。他们均在专门的BTX-A诊所接受了评估、注射和随访。患者被要求完成一份经过验证的PREM——客户满意度问卷（CSQ-8）——以及我们科室编制的一份问卷，以评估对治疗效果的满意度。大多数患者通过门诊局部麻醉软性膀胱镜技术接受了200单位的注射用A型肉毒毒素（保妥适（®））。
72名患者有完整数据。总共有49名患者继续接受BTX-A治疗，而23名患者选择不再注射。CSQ-8总体平均（标准差）满意度得分为38.3（3.3），表明患者对我们机构提供的服务满意度较高。仍在接受BTX-A治疗的患者（平均得分29.8）和已停止治疗的患者（平均得分25.1）之间的总体满意度得分存在显著差异（P < 0.01）。患者对治疗效果的总体满意度较高，在视觉模拟量表上的总体平均（标准差）得分为8.6（2.0）。在已停止使用BTX-A的患者中，大多数要么仅采用保守措施（44%），要么重新开始使用抗胆碱能药物。
患者对我们机构提供的专门BTX-A服务总体满意度较高，可带来积极的患者体验。提倡使用PREM，以便全面了解患者对所接受服务和治疗质量的看法。
